News articles about Insulet (NASDAQ:PODD) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Insulet earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned headlines about the medical instruments supplier an impact score of 45.933229722069 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:
Shares of Insulet (PODD) traded down $0.06 during mid-day trading on Thursday, reaching $68.73. 469,746 shares of the company’s stock were exchanged, compared to its average volume of 503,114. Insulet has a twelve month low of $36.05 and a twelve month high of $72.99. The company has a quick ratio of 4.42, a current ratio of 4.88 and a debt-to-equity ratio of 4.65.
Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.06. Insulet had a negative net margin of 6.66% and a negative return on equity of 43.85%. The business had revenue of $121.80 million during the quarter, compared to the consensus estimate of $114.02 million. During the same period in the prior year, the firm posted ($0.05) EPS. The firm’s quarterly revenue was up 28.4% compared to the same quarter last year. equities analysts expect that Insulet will post -0.42 EPS for the current year.
Several research firms have weighed in on PODD. Barclays began coverage on shares of Insulet in a research note on Friday, September 15th. They issued an “overweight” rating and a $65.00 price target for the company. Jefferies Group lifted their price target on shares of Insulet from $58.00 to $67.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Canaccord Genuity raised shares of Insulet from a “hold” rating to a “buy” rating and boosted their target price for the stock from $50.00 to $65.00 in a research report on Wednesday, November 1st. Zacks Investment Research downgraded shares of Insulet from a “buy” rating to a “hold” rating in a research report on Saturday, November 11th. Finally, BidaskClub raised shares of Insulet from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 25th. Eight research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $61.07.
In other news, Director James C. Mullen acquired 2,500 shares of Insulet stock in a transaction on Monday, November 13th. The stock was acquired at an average cost of $67.45 per share, with a total value of $168,625.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.90% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2017/12/07/insulet-podd-receiving-somewhat-positive-media-coverage-accern-reports.html.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Co. and related companies with MarketBeat.com's FREE daily email newsletter.